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Individuals with a social anxiety disorder (SAD) show hypofunctioning of the hypothalamus–pituitary-gonadal (HPG) axis, which is
linked to social fear and avoidance behavior. As testosterone administration has been shown to facilitate social-approach behavior
in this population, it may enhance the effectiveness of exposure treatment. In this proof-of-concept study, we performed a
randomized clinical assay in which 55 women diagnosed with SAD received two exposure therapy sessions. Session 1 was
supplemented with either testosterone (0.50 mg) or placebo. Next, transfer effects of testosterone augmentation on within-
session subjective fear responses and SAD symptom severity were assessed during a second, unenhanced exposure session
(session 2) and at a 1-month follow-up, respectively. The participants having received testosterone showed a more reactive fear
pattern, with higher peaks and steeper reductions in fear levels in session 2. Post-hoc exploration of moderating effects of
endogenous testosterone levels, revealed that this pattern was specific for women with high basal testosterone, both in the
augmented and in the transfer session. In contrast, the participants with low endogenous testosterone showed reduced peak fear
levels throughout session 1, again with transfer to the unenhanced session. Testosterone did not significantly affect self-reported
anxiety. The effects of testosterone supplementation on fear levels show transfer to non-enhanced exposure, with effects being
modulated by endogenous testosterone. These first preliminary results indicate that testosterone may act on important fear
mechanisms during exposure, providing the empirical groundwork for further exploration of multi-session testosterone-enhanced
exposure treatment for SAD.
Translational Psychiatry          (2021) 11:432 ; https://doi.org/10.1038/s41398-021-01556-8
INTRODUCTION
With a lifetime prevalence of 13% and long-term disability, social
anxiety disorder (SAD) is the most common and burdensome of all
anxiety disorders [1–3]. Persistent avoidance is the main factor
hindering the extinction of fear during social situations, which is
why reducing avoidance behavior is the core target of exposure
therapy, the treatment of choice for SAD [4, 5]. However, with
response rates of 45–55%, the intervention leaves room for
improvement [6–9]. Particularly, augmentation strategies aimed at
alleviating social avoidance and promoting social approach have
the potential to boost core mechanisms assumed to underlie the
effects of exposure in SAD.
Previous attempts to enhance the therapy’s efficacy with
pharmacological agents (e.g., d-cycloserine (DCS), yohimbine,
oxytocin) targeted the process of extinction learning in SAD
[10–15]. Although the results are encouraging, no pharmacologi-
cal enhancer has been tested that directly acts on acute within-
session social-approach behavior, essential for effective exposure.
Testosterone, the end product of the hypothalamus–pituitary–
gonadal (HPG) axis, is important in the regulation of social
motivational behavior, including approach and avoidance beha-
vior [16]. In both animal and human studies, low endogenous
testosterone has been linked to socially submissive, anxious, and
avoidant behaviors [17–19], while high basal testosterone is
related to social dominance and approach behavior [20, 21].
Importantly, in individuals with SAD [22] and other social
avoidance-related disorders such as depression [22, 23] reduced
levels of endogenous testosterone have been found. Moreover,
relatively high pre-treatment testosterone concentrations pre-
dicted a better outcome of exposure therapy in terms of larger
symptom reductions [24]. Additionally, causal studies on the
relationship between testosterone and avoidance behavior further
confirm the social avoidance-reducing and approach-facilitating
properties of testosterone [25–27]. Testosterone acts on dopami-
nergic projections from the amygdala to the striatum and its
administration was shown to bias amygdala activity toward social
threat approach in humans [28, 29]. At a behavioral level,
testosterone administered to healthy participants prior to threat
exposure was found to reduce fear, enhance reward sensitivity,
and promote social-approach motivation [25, 26, 30]. Eye-tracking
and electrophysiological studies by our group showed that, when
administered to women with SAD, testosterone reduced auto-
matic threat bias to angry faces [31, 32], diminished social
avoidance, and promoted prosocial behavior, including approach
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toward angry faces [27]. Although preliminary, these findings
provide promising evidence that testosterone administration prior
to exposure therapy enhances the treatment’s efficacy by
promoting social approach, one of its main goals [24, 33].
Given its profound role in the regulation of social motivational
behavior, in the present proof-of-concept study, we test the
augmentation effects of testosterone on exposure in women
coping with SAD in a randomized clinical assay, comparing a
single testosterone-enhanced session (0.50 mg) with a placebo-
supplemented session. To assess the transfer of testosterone-
induced effects, the participants engaged in a similar but
unenhanced exposure session one week later. We hypothesized
that, compared to the placebo group, testosterone-enhanced
exposure would induce steeper reductions in subjective fear
during the repeated exposure session, as an index of retention of
extinction learning during session 1 [34–36]. In addition, we
verified whether testosterone supplementation would affect self-
reported pre-to-post-treatment social anxiety symptoms. Finally,
we explored the physiological effects of acute testosterone
administration by assessing within-session HR. Given the recent
insight into the moderating effects of endogenous testosterone
on exogenous testosterone [37–39] and the efficacy of exposure
treatment for SAD in particular [24], we explored endogenous
testosterone as a moderating factor in our analyses.
MATERIALS AND METHODS
Participants
Participants were recruited from an outpatient clinic specializing in the
treatment of anxiety disorders, from the Radboud University Nijmegen,
and from the community from 2017 through 2019. Inclusion criteria were:
(1) woman, (2) age: 18–45 years, (3) primary diagnosis of SAD (as assessed
with the Mini International Neuropsychiatric Interview (MINI; [40]), with a
predominant fear of public speaking, and (4) score >30 on the Liebowitz
Social Anxiety Scale (LSAS; [41]). We focused exclusively on women
because the pharmacodynamics of the currently used testosterone
administration methods have as yet been established in women only
[42]. Exclusion criteria were: (A) prior non-response to speech exposure
therapy for SAD, (B) other predominant mental disorder(s), (C) (current or
lifetime) psychosis or delusion disorders, (D) significant suicidal ideation or
behavior within 6 months prior to screening, (E) intellectual disability, (F)
substance or alcohol dependence, (G) somatic illness, H) unwillingness to
use an active form of birth control during the trial, (I) pregnancy or
lactation, (J) infertility, (K) antipsychotic medication, (L) unstable regimen
of antidepressants or benzodiazepines within 6 weeks prior to enrollment,
(M) insufficient proficiency in the Dutch language, (N) current use of
contraceptives containing cyproterone acetate. All participants received 70
Euros for their participation. Ethical approval for this study was granted by
the local (Arnhem-Nijmegen) Review Board.
In total, 55 women suffering from SAD (Mage= 23.31, SD= 5.63, range=
18–43) were included in the study sample. One participant dropped out
before the first exposure session (due to illness). She was replaced by
another participant to ensure equal group sizes, resulting in 55 participants
receiving the allocated drug (testosterone/placebo) and 54 the exposure
sessions: 27 per group (see Supplementary Fig. S1 for CONSORT flowchart).
After study completion, one participant (testosterone group) divulged she
had been on atypical antipsychotic quetiapine, which fact she had not
mentioned during eligibility screening. Since she had consistently used a
low, stable dose (25mg) for the last 18 months, we decided not to exclude
her from the analyses.
Medication and randomization
The pharmacist providing the study solutions randomly assigned participants
to testosterone (T) or placebo (P) in blocks of four (no stratification). T was
suspended in a clear solution (0.5ml) with 0.5mg hydroxypropyl-beta-
cyclodextrin, 0.005ml ethanol 96%, and distilled water. P contained the same
ingredients, barring T. Participants held the liquid under their tongues for
60 seconds. In women, this dose yields a sharp increase in plasma
testosterone concentrations within 15min and declines to baseline within
90min [43]. Pharmacodynamic effects can be assayed 4–6 h after intake
[30, 42]. Researchers, therapists, and participants were blinded to the group
allocation until the completion of the primary outcome analyses.
Exposure intervention
The participants engaged in two 90-min public-speaking exposure
sessions delivered one week apart in accordance with the protocols
developed by Rodebaugh and colleagues [10, 13]. The sessions were
standardized with respect to exposure length (6–8 min), preparation time
(max. 5 min), reaction of the experimenter (neutral), and the availability of
notes and speech topic. On the morning of the first day, the participants
received psychoeducation about SAD and exposure, with the first session
starting after 4 h. In both sessions, psychoeducation was repeated and
personalized harm expectancies and goals were assessed. Then, the
participants presented their prepared speech in front of a therapist, two
confederates, and a camera. They reviewed their videotaped perfor-
mance afterward together with the therapist. The therapists were
psychology students in their last year of training (BA and MA level)
trained and supervised by experienced, board-certified psychologists (M.
H.M.H. and M.K). To guarantee adherence to the protocol, the therapists
were instructed to fill out a checklist of all protocol components and to
report any deviations from the protocol. The checklists and reports on
deviations showed that 96.3% of the sessions were delivered in
accordance with the protocol.
Outcome measures
Within-session fear (primary outcome). Participants rated their fear levels
on a subjective units of distress (SUD) scale ranging from 0: No fear to 100:
Extreme fear [44]. SUDs were collected after psychoeducation (initial SUD),
immediately prior to each exposure session (baseline SUD), immediately
prior to the speech (start SUD), every 2 min during, and immediately after
the speech (endpoint SUD).
Symptom severity (secondary outcome). Social anxiety symptoms were
assessed with the Social Phobia Scale (SPS; [45]), a self-report measure
assessing the fear of being observed or watched during social or
performance situations. The scale has shown good internal consistency
([45]; α= 0.94; Dutch translation; [46], α= 0.91, current study α= 0.86).
Participants completed the SPS at baseline, after the second exposure
session (post-treatment) and at the 1-month follow-up (FU) assessment.
Saliva samples. To determine endogenous testosterone levels, saliva
samples were collected (2 ml passive drool saliva by Salicap; Hamburg,
Germany) at eight time points (Fig. 1): (1) at baseline, (2) prior to T/P
intake, (3) prior to exposure session 1, (4) immediately after speech
delivery in session 1, (5) 30 min after speech delivery in session 1, (6)
prior to exposure session 2, (7) immediately after speech delivery in
session 2, and (8) 30 min after speech delivery in session 2. Participants
were asked to conform to certain directives regarding food and drink
intake to prevent pollution of the saliva samples. Samples were stored at
−20 °C until radio-immune assays were performed at Dr. Kirschbaum’s
laboratory (Dresden, Germany); for descriptions of the methodology, see
refs. [47, 48].
Procedure. After having provided their informed consent, participants
were screened online for eligibility, to which end they filled out the LSAS
and answered general screening questions (e.g., age, treatment status,
infertility, menstrual cycle). Eligible participants were telephoned for
further screening (MINI, check in/exclusion criteria), after which they
learned whether they would be participating in the study (see supplement
for details). All other assessments and the exposure sessions took place at
the treatment facility. After enrollment (see Fig. 1 for timing and
procedure), participants completed the baseline assessment1, with the
first exposure session being scheduled within one week. The morning of
the session, the participants took a pregnancy test, saliva was collected,
and psychoeducation provided, after which the participants completed a
non-speech-related SUD and received T/P (administered by a research
assistant). After 4 h, during which time participants were instructed to
avoid physically and psychologically straining activities and heavy meals,
they returned for the exposure session, before which saliva was collected
and resting HR was recorded. Another saliva sample was collected
immediately upon completion of the speech and 30min thereafter. During
the speech, SUDs and HRs were collected. At the end of the session, the
therapist checked for adverse drug effects by asking participants about
1Computerized tasks were also part of the baseline assessment, but
outcomes will be reported elsewhere.
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physical complaints. A week later, the second exposure session took place,
with all steps being identical to those of the first session barring
supplement administration. After a 30-min break, participants took the
post-exposure assessment comprising the SPS and a computer task
(reported elsewhere). We asked all participants to refrain from using
alcohol, drugs, or medication (except from their stable dose of
psychotropic medication) during testing days. One month later, partici-
pants once again completed the SPS online. This study was registered in
the Dutch Trial Register: https://www.trialregister.nl/trial/6238 and at
EudraCT (2014–004475–23).
Statistical analyses
To test the effects of testosterone augmentation on subjective fear, we
used mixed models. A sample size of 52 participants was deemed
necessary to detect group differences with at least a moderate effect size
and a power of 80%. We tested the acute effects of the enhancement
(session 1) and transfer to unenhanced exposure (session 2) separately. Its
effects on SAD symptoms (SPS scores) were tested in an additional model
(see below). Moreover, we explored augmentation effects on HR in similar
models as subjective fear (see supplementary materials for details). We
used the Lme4 package in R [49] and p-values were calculated using the
likelihood ratio tests (Afex package) [50]. Independent continuous
predictors were centered and sum-to-zero contrasts used. Consistent with
the recommendations for mixed models [51], we report unstandardized
effect sizes (estimates).
More specifically, to determine whether the added testosterone had
affected self-reported fear (SUDs) during session 1, group (T/P) and time
(start, 2 min, 4 min, 6 min, 8 min, end) were included as predictors. Linear,
quadratic, and cubic time terms were modeled since we expected that the
SUD scores would not necessarily follow a linear pattern (e.g., they could
increase first [fear activation] before they decrease). Participant was
included as random intercept and time (linear, quadratic, cubic) as random
slope. Initial SUDs (rated after psychoeducation) were included as a fixed
factor to control for variance unrelated to time or group; see also ref. [13].
To examine whether enhanced exposure affected fear patterns during the
second unenhanced session, we ran the same analysis used for the first
session. As regards the effects of the enhancement on symptom severity,
we modeled SPS scores, with group (T/P) and time (pre/post/FU) as
predictors and participant as the random intercept.
Finally, in light of recent insights into the role of endogenous
testosterone on the effects of exposure treatment for SAD [24], we
conducted post-hoc tests, re-running all our analyses now including basal
testosterone levels (mean samples 1 and 2). Since we detected some
outliers (visual inspection of boxplots) in the baseline data, we repeated
the analyses after winsorizing (i.e., setting extreme baseline testosterone
values to the second and 98th percentile to thus reduce the effects of
spurious outliers). The results remained unchanged. Also, given that age
and hormonal birth control are known factors affecting endogenous
testosterone, we checked if the observed effects would hold after
correcting for these variables in all models.
RESULTS
Attrition
One participant receiving placebo dropped out before the first
exposure due to illness (see participant section). Another
participant in the same group dropped out during the first
session (3.6%). All other participants completed both sessions and
the follow-up.
Sample characteristics
The data of 54 participants were analyzed (Mage= 23.31, SD=
5.64, range = 18–43; Table 1). There were no significant between-
group differences on any of the baseline measures. The
manipulation was successful: compared to the placebo group,
testosterone levels after testosterone administration (sample 3)
were significantly higher in the enhanced group, moreover
blinding was successful, participants were unaware if they
received T or P (Table 1).
Adverse events
The testosterone and placebo arms did not differ with respect to
adverse events; no serious events were reported in either group
(for details see supplement).
Acute effects of testosterone augmentation (session 1)
Fear. Before reporting on the critical transfer session (2), we first
describe the acute effects of testosterone on fear scores in session
1. Fear scores decreased over time (linear and quadratic), with
exposure resulting in the expected within-session reduction:
Estimate(linear)=−81.96 (16.76), F(1,51)= 23.89, p < 0.001, Esti-
mate(quadratic)= −85.12(13.99), F(1,51)= 36.95, p < 0.001. The
interaction between time (linear or quadratic) and group was not
significant: p-values > 0.618 (for details see supplement and
Supplementary Fig. S2A).
In the post-hoc model including baseline testosterone levels, the
effects of time were confirmed: p-values < 0.049. There was no
significant time × group interaction, p-values > 0.562 (see Supple-
mentary section), but the effect for time(quadratic) × group ×
baseline-T effect was significant: Estimate= 2.26(0.94), F(1,48)= 5.72,
p= 0.021. As to fear patterns as a function of endogenous
testosterone, in the placebo group, fear was not moderated by
baseline testosterone: Estimate= 0.82(1.14), F(1,24)= 0.52, p= 0.476.
In contrast, in the testosterone group, fear patterns in the participants
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Fig. 1 Timing and procedure of the study protocol. SPS Social
Phobia Scale, SUD subjective units of distress, T testosterone, P
placebo, HR heart rate. Since pregnancy was a reason for exclusion,
the pregnancy test was to ascertain that none of our participants
was pregnant prior to the start of the testosterone-enhanced
session.
M.H.M. Hutschemaekers et al.
3
Translational Psychiatry          (2021) 11:432 
showing higher peaks followed by stronger reductions, than in those
with lower values, where fear responses were characterized by
relatively blunted peaks followed by weaker reductions: Estimate=
−3.73(1.48), F(1,24)= 6.32, p= 0.019 (Fig. 2A). Inclusion of age or
hormonal contraceptives did not improve the fit of any of the
models, so these were dropped from the analyses.
Transfer effects of testosterone augmentation (session 2)
Fear. Next, we tested effects for the critical unenhanced session
(2). Fear reduced over time2: Estimate(linear)=−62.95(15.42),
F(1,50)= 16.66, p < 0.001, Estimate(quadratic)=−48.32(11.03),
F(1,50)= 19.18, p < 0.001, Estimate(cubic)=−36.76(8.90), F(1,50)
= 17.01, p < 0.001. Critically, there was a group × time(quadratic)
interaction: Estimate= 23.68(11.03), F(1,50)= 4.61, p= 0.037.
Compared to participants having received placebo, the partici-
pants in the testosterone group showed a more reactive fear
pattern (higher SUDs) with a steeper decline at the end of the
session (Supplementary Fig. S2B).
The post-hoc observation that testosterone administration had
resulted in steeper fear reductions in participants with high
baseline testosterone (session 1) was again made in the second,
non-enhanced session, with fear levels showing a similar time
(quadratic) × group × Baseline-T interaction: Estimate= 1.53(0.74),
F(1,47)= 4.22, p= 0.045. In the placebo group, session-2 fear
levels followed the same quadratic pattern regardless of baseline
testosterone: Estimate= 0.77(0.82), F(1,23)= 0.94, p= 0.357. In the
testosterone group, they showed higher peaks followed by
stronger reductions for participants with high baseline testoster-
one, whereas for those with low baseline testosterone peak fear
levels flattened: Estimate=−2.29(1.27), F(1,23)= 3.26, p= 0.084
(Fig. 2B).
Post-hoc exploration of heart rate in sessions 1 and 23. Our results
so far suggest that testosterone may have an acute impact on
exposure mechanisms, boosting a steeper fear-decline in indivi-
duals with high baseline testosterone levels in session 1, which
could be relevant for the subsequent transfer to session 2. To
deepen our understanding of potential mechanisms affected
during session 1, we post-hoc explored whether psychophysiolo-
gical reactivity (HR) mimics the acute effects of testosterone
administration on fear levels. HR patterns largely mimicked those
of the subjective fear patterns in session 1: There was a non-
significant trend toward a time(linear) × group × baseline-T
interaction: Estimate= 0.80(0.42), F(1,44)= 3.64, p= 0.063. In the
placebo group HR decline followed the same slope regardless of
baseline testosterone: Estimate= 0.04(0.03), F(1,23)= 0.056, p=
0.461, while in the testosterone group HR reduced more for the
participants with higher baseline testosterone levels: Estimate=
−0.12(.06), F(1,21)= 3.89, p= 0.061. These acute psychophysiolo-
gical effects did not transfer to the non-enhanced transfer session,
indicating that they may support the acute fear reactivity, but that
it is the subjective fear pattern that is longer-term affected (for full
analyses see supplement and Supplementary Fig. S3).










t or χ2, p
Demographics
Age 23.31 (5.64) 24.00 (6.85) 22.61 (4.12) 0.90, 0.372
SPS total score 30.20 (11.85) 32.15 (13.82) 28.26 (9.35) 1.21, 0.232
LSAS total score 63.06 (19.24) 64.70 (18.96) 61.41 (19.73) 0.62, 0.534
Initial SUD score 20.59 (13.86) 20.44 (11.33) 20.74 (16.21) 0.77, 0.938
Testosterone sample 1 15.17 (16.41) 15.94 (19.65) 15.47 (12.76) 0.105, 0.917
Testosterone sample 2 16.21 (15.45) 17.57 (16.83) 14.80 (14.06) 0.650, 0.518
Testosterone sample 3 252.49 (380.03) 15.29 (16.19) 489.68 (421.06) −5.85, <0.001
Educational level (n) 1.15, 0.680
High school 7 2 5
Intermediate vocational 6 3 3
Higher vocational 11 6 5
University 30 16 14
Psychological treatment (n) 9 5 4 0.13, 0.715
Psychotropic medication use (n) 4 2 2 2.00, 0.572
Contraceptive use (n) 1.29, 0.733
Hormonal 30 15 15
Non-hormonal 24 12 12 0.00, 1.00
Comorbid anxiety disorder (n) 18 11 7 1.39, 0.239
Comorbid depressive disorder (n) 5 2 3 0.22, 0.639
Participants believed to be in T group (n) 12 7 5
For testosterone sample 2 in the testosterone group, n= 26 as one participant had a missing value. Testosterone values are in picograms per milliliter (pg/ml).
(n) = values are expressed as number of participants.
SPS Social Phobia Scale, LSAS Liebowitz Social Anxiety Scale, SUD subjective units of distress.
2The residuals of the models for the SUDs in session 2 and the SAD
symptom scores showed one standardized value >3; therefore, the
models were re-run without this outlier. Since our primary outcomes
were similar, the results presented include all data points.
3We initially modeled linear, quadratic, and cubic time terms in all HR
analyses but dropped the cubic term as it did not improve the
model fit.
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The effect of testosterone administration on social anxiety
symptoms
SAD symptoms decreased from pre- to post-treatment (Mpre=
30.20 vs. Mpost= 28.04), Estimate=−2.22(1.23), t(1,102)=−1.80,
p= 0.074 and significantly so from pre- to FU: Estimate=−7.02
(1.23), t(1,102)=−5.70, p < 0.001 (Mpre= 30.20, MFU= 23.26).
There was no group × time interaction: pre-post, Estimate=
−0.48(1.23), t(1,102)=−0.39, p= 0.697, pre-FU: Estimate=−2.10
(1.23), t(1,102)=−1.70, p= 0.092, indicating that symptom
severity after treatment discontinuation did not show any of the
effects of testosterone enhancement on within-session fear. There
was no effect of baseline testosterone.
DISCUSSION
Seeking to test the effects of testosterone-augmented exposure
treatment for individuals with SAD, we compared a single
exposure session with testosterone supplementation (0.50 mg)
to an exposure session with placebo, assessing fear levels in an
unenhanced second session and SAD severity after one month.
The exposure sessions were successful in reducing fear, HR, and
SAD symptoms, independent of group. Foremost, testosterone
augmentation was associated with higher peaks followed by a
steeper decline in fear at the end of the second unenhanced
session. Post-hoc analyses revealed this pattern was most
pronounced in participants with higher baseline testosterone
and evident in both the enhanced (session 1) and the transfer
session (session 2). Peak fear levels in the participants with low
basal testosterone remained lower throughout both sessions.
Testosterone enhancement did not significantly change SAD
symptom severity. Our proof-of-concept results provide prelimin-
ary support that testosterone may act on important mechanisms
of exposure, meriting further examination of multiple-session
testosterone-enhanced exposure therapy for SAD.
The effects of testosterone partly coincide with several studies
supporting avoidance-reducing and social-approach-facilitating
properties of the hormone [25–27]. Moreover, the SUD patterns
(increase prior to a decrease) are in line with Emotional Processing
Theory (EPT) positing that fear needs to be activated first, and only
after prolonged exposure, fear levels will drop. Such reactive
pattern is deemed essential for learning and, hence, transfer in the
long run [34, 35]. By boosting initial engagement with the feared
stimulus, testosterone may affect important learning mechanisms
reinforcing transfer (e.g., initial engagement to the feared stimulus
in session 1 that transfers to fear levels in a second unenhanced
session). Such interpretation is in line with the threat-approach
boosting effects of testosterone in patients with social anxiety
disorder [27, 31].
Then again, acute testosterone-augmentation effects depended
on endogenous testosterone levels. This is consistent with
evidence showing that individual differences in basal testosterone
and proxies of fetal testosterone exposure (2D:4D ratio) moderate
the effects of exogenous testosterone on various pertinent
behavioral processes, including social approach, aggression,
dominance, and risk-taking [37–39, 52, 53].
The interaction between endogenous testosterone levels and
exogenous testosterone administration was interesting and
deepen our understanding of the primary results, in that
exclusively the participants with low baseline concentrations
having received testosterone reported blunted peak fear levels.
This is in line with earlier findings regarding the anxiolytic
properties of testosterone [30, 54]. Together, these findings
suggest that women with relatively low endogenous testosterone
show lowered threat response following testosterone supplemen-
tation that transfers to the non-enhanced session. In contrast,
although the women with higher basal testosterone reported
similar fear levels at the end of the enhanced session, they arrived
there via a different, more fear-reactive route that appeared to be
transferred to the unenhanced session. Arguably, the
testosterone-induced effects (e.g., higher peak fear) in women
with higher endogenous levels could be interpreted as negative.
However, in theoretical accounts of exposure therapy (i.e., EPT [35]
Placebo Testosterone
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B. Session 2 (unenhanced transfer session)
Fig. 2 Subjective fear levels during exposure as a function of baseline testosterone per group (T/P). The figure illustrates the evolution of
subjective fear levels during exposure with placebo (P) or testosterone (T) (session 1; A) and unenhanced exposure indicating transfer after P
and T (session 2; B). Fear, expressed in subjective units of distress (SUDs), is displayed over time as a function of baseline-T. In order to visualize
the interaction effect between baseline-T and time, we subdivided baseline-T into low (−1 SD), medium (mean), and high (+1 SD) values.
Thus, the plot shows model-based predicted values, illustrating that high baseline-T is associated with higher SUD reactivity during
testosterone-enhanced exposure (session 1), a pattern that largely transfers to the second unenhanced exposure (session 2). Note that for
both groups there is no correlation between baseline-T and start SUDs in session 1 (rplacebo=−0.07, p= 0.73; rtestosterone= 0.06, p= 0.788) or
session 2 (rplacebo=−0.03, p= 0.873; rtestosterone= 0.14, p= 0.472), indicating that effects are not driven by differences in start SUDs as a
function of baseline-T but merely reflect differences in within-session fear patterns.
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and inhibitory learning theory [36, 55]) high fear levels during
(initial) exposure sessions are deemed beneficial for a good
response, prompting the hypothesis that, it may facilitate essential
exposure mechanisms in those with high basal levels. In the
present proof of concept study, we cannot yet verify such
qualification of patterns as beneficial or not, particularly as our
single session-enhancement did not result in lower SUD levels at
the end of the second exposure, in the testosterone compared to
placebo group. We can only make speculations based on
theoretical grounds and clearly, treatment protocols with more
exposure sessions are needed to further elucidate the effects of
exogenous testosterone on fear activation and reduction within
and across exposure sessions.
That endogenous testosterone moderates the effects of
exogenous testosterone may be explained by trait factors,
including individual differences in the sensitivity of the
androgen receptor (AR), where relative AR insensitivity has
been reported for people with low basal concentrations [56, 57].
Moreover, testosterone administration can lead to AR down-
regulation in hypogonadal mice and human males, while long-
lasting effects of endogenous testosterone may upregulate its
expression [58].
The observed effects of exogenous testosterone on fear levels
did not generalize to SAD symptoms. Although we extend
previous observations that a single dose of testosterone can
affect threat-approach behavior in SAD in an experimental context
[27, 31], to fear-reactivity in a clinical context, we do not observe
an effect on clinical outcomes. This may be a result of the fact that
our symptom outcome measure (SPS) only has one item
measuring speech anxiety. We recommend future studies to use
a measure more sensitive to changes in speech anxiety. On the
other hand, research testing other pharmacological enhancers
demonstrated that repeated doses yielded better exposure
outcomes than did a single dose [14, 59] So, future investigations
comprising more testosterone-enhanced sessions are necessary to
establish whether testosterone can improve SAD symptoms.
As to the strengths of our study, we can say that with a
comparative randomized clinical assay we were able to establish
that the administration of a single dose of testosterone was safe
and tolerable; there were no adverse events or augmentation-
related drop-out. Moreover, by comparing effects in two
successive sessions, we were able to examine the direct effects
of the enhancement and their transfer in a relatively quick and
cost-effective manner. However, since we only included women
because the administration method we used has as yet only been
applied in women [42], we cannot say whether our findings will
generalize to men. Also, due to inclusion restrictions (e.g., birth
control types, pregnancy) and because women with relatively low
endogenous testosterone were relatively underrepresented, it
remains to be tested whether findings generalize to a broader
group and replication in a larger, more varied sample is needed.
Furthermore, although all our participants met the SAD criteria,
their baseline severity scores were somewhat lower than those
reported in other exposure enhancement studies [11, 14, 60]. Even
though our findings show that exogenous testosterone already
exerts effects in a population with relatively mild symptoms, it
needs to be shown whether they generalize to more severely
impaired populations.
To conclude, testosterone-augmented exposure differentially
affects in-session fear levels, partly depending on baseline
testosterone levels of individuals with SAD. It reduced self-
reported peak fear levels in individuals with low baseline
testosterone, and increased reactive patterns in individuals with
high baseline testosterone. Because both patterns may be
relevant for long-term extinction learning, we hope this study
inspires an investigation of the longer-term effects of repeated
testosterone-enhancements in SAD.
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